AtriCure Inc
ATRC
View Detailed Chart
35.660USD
+0.650+1.86%
Market hours （ET）Quotes delayed by 15 min
1.77BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.86%
5 Days
+1.45%
1 Month
+0.59%
6 Months
+5.57%
Year to Date
+16.69%
1 Year
+27.04%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
51.000
Target Price
+41.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.84% year-on-year.
Fairly Valued
The company’s latest PE is -45.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.65M shares, decreasing 9.96% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.90M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Ticker SymbolATRC
CompanyAtriCure Inc
CEOMr. Michael H. (Mike) Carrel, CPA
Websitehttps://www.atricure.com
Related Instruments
+0.25%
-0.17%
-0.35%
+0.39%
+0.42%
+0.57%
-0.01%
-3.11%
+0.45%
+1.29%
-0.27%
-0.06%
-0.64%
+3.62%
+1.15%
+1.45%
+0.13%
+0.71%
+1.35%
+2.43%
